PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-17.13%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-56.88%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
64.12%
EBIT growth 75-90% of RUN's 85.34%. Bill Ackman would push for cost reforms or better product mix to narrow the gap.
-44.93%
Negative operating income growth while RUN is at 85.34%. Joel Greenblatt would press for urgent turnaround measures.
26.00%
Net income growth under 50% of RUN's 67.26%. Michael Burry would suspect the firm is falling well behind a key competitor.
-294.44%
Negative EPS growth while RUN is at 67.48%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
86.35%
Diluted EPS growth 1.25-1.5x RUN's 67.48%. Bruce Berkowitz would verify if strategic moves (e.g., targeted acquisitions, cost cuts) explain the edge.
-0.04%
Share reduction while RUN is at 0.51%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
0.06%
Diluted share reduction more than 1.5x RUN's 0.51%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-39.92%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-89.21%
Negative FCF growth while RUN is at 4.05%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
-61.22%
Negative 10Y revenue/share CAGR while RUN stands at 211.68%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-37.05%
Negative 5Y CAGR while RUN stands at 10.57%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
1.50%
3Y revenue/share CAGR under 50% of RUN's 42.03%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
-159.44%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
13.70%
Positive OCF/share growth while RUN is negative. John Neff might see a comparative advantage in operational cash viability.
-281.16%
Negative 3Y OCF/share CAGR while RUN stands at 32.42%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-185.83%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
85.92%
Positive 5Y CAGR while RUN is negative. John Neff might view this as a strong mid-term relative advantage.
-106.52%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-81.01%
Negative equity/share CAGR over 10 years while RUN stands at 484.18%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
218.02%
5Y equity/share CAGR 1.25-1.5x RUN's 183.34%. Bruce Berkowitz confirms if reinvested profits or buybacks explain the superior buildup.
-26.48%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.64%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-19.39%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-6.93%
Negative asset growth while RUN invests at 2.11%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-27.56%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
4.38%
Debt growth far above RUN's 4.49%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-11.23%
Our R&D shrinks while RUN invests at 52.07%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
8.26%
SG&A growth well above RUN's 2.81%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.